Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-07
2011-06-07
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S300000, C530S324000, C424S009100
Reexamination Certificate
active
07956030
ABSTRACT:
The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
REFERENCES:
patent: 5051403 (1991-09-01), Miljanich et al.
patent: 5189020 (1993-02-01), Miljanich et al.
patent: 5364842 (1994-11-01), Justice et al.
patent: 5559095 (1996-09-01), Miljanich et al.
patent: 5587454 (1996-12-01), Justice et al.
patent: 5795864 (1998-08-01), Amstutz et al.
patent: 5891849 (1999-04-01), Amstutz et al.
patent: 5980927 (1999-11-01), Nelson et al.
patent: 6054429 (2000-04-01), Bowersox et al.
patent: 6136786 (2000-10-01), Justice et al.
patent: 6379882 (2002-04-01), Bitler et al.
patent: 2196848 (1988-05-01), None
patent: WO 93/13128 (1993-07-01), None
patent: WO 97/01351 (1997-01-01), None
patent: WO 01/76576 (2001-10-01), None
patent: WO 01/83555 (2001-11-01), None
patent: WO 03/078408 (2003-09-01), None
patent: WO 2005/032556 (2005-03-01), None
Basilico, et al.; “Influence of w-Conotixin on Morphine Analgesia and Withdrawal Syndrome in Rats”;European Journal of Pharmacology; vol. 218 (1992) pp. 75-81.
Bennett, et al.; “Evidence-Based Review of the Literature on Intrathecal Delivery of Pain Medication”;Journal of Pain and Symptom Management; vol. 2 No. 2 (Aug. 2, 2000) pp. S12-S36.
Coffey, et al.; “Inflammatory Mass Lesions Associated with Intrathecal Drug Infusion Catheters: Report and Observations on 41 Patients”;Neurosurgery;vol. 50, No. 1 (Jan. 2002) pp. 78-87.
Follett, et al.; “Intrathecal Analgesia and Catheter-tip Inflammatory Masses”;Anesthesiology; vol. 99, No. 1 (Jul. 2003) pp. 5-6.
Gradert, et al.; “Safety of Chronic Intrathecal Morphine Infusion in a Sheep Model”;Anesthesiology,vol. 99, No. 1 (Jul. 2003) pp. 188-198.
Horvath, et al.; Role of Calcium channels in the Spinal Transmission of Nociceptive Informatin From the Mesentery;International Study of Pain; vol. 93 (2001 pp. 35-41.
Hassenbusch, et al.; “Current Practices in Intraspinal Therapy—A Survey of Clinical Trends and Decision Making”;Journal of Pain and Symptom Management; vol. 20 No. 2 (Aug. 2000) pp. S4-S11.
Hassenbusch, et al.; “Polyanalgesic Consensus conference 2003:An Update on the Management of Pain by Intraspinal Drug Delivery—Report of an Expert Panel”;Journal of Pain and Symptom Management; vol. 27 No. 6 (Jun. 2004) pp. 540-563.
Krames , et al.; “Intrathecal Infusional Analgesia for Nonmalignant Pain; Analgesic Effecacy of Intrathecal Opioid With or Without Bupivacaine”;Journal of Pain and Symptom Management; vol. 8 No. 8 (Nov. 1993) pp. 539-548.
McMillan et al.; “Catheter-Associated Masses in Patients Receiving Intrathecal Analgesic Therapy”;Anesthesia Analogy; vol. 96 (2003) pp. 186-190.
Saulino, M. et al., “Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity:case reports”,Eur J Phys Rehabil Med 2009,vol. 45 (2009), pp. 1-7.
Smith, et al.; “Influence of Voltage-Sensitive CA++Channel Drugs on Bupivacaine Infiltration Anesthesia in Mice”;Anastesiology; vol. 95 (2001) pp. 1189-1197.
Wang, et al.; “Interactions of Intrathecally Administered Ziconotide, a Selective Blocker of Neuronal N-Type Voltage-Sensitive Calcium Channels, with Morphine on Nociception in Rats”;Pain; vol. 84 (2000); pp. 271-281.
Wang, et al.; “Ziconotide Chemistry and Blockade of N-Type VSCCS”;CNS Drug Review; vol. 6, No. 1 (2000) pp. 2-20.
Wei, et al.; “Spinal Morphine/Clonidine Antinociceptive Synergism; Involvement of G Proteins and N-Type voltage-Dependent Calcium Channels”;The Journal of Pharmacology and Experimental Therapeutics; vol. 278, No. 3 (1996) 1392-1407.
Yaksh, et al.; “Chronically Infused Intrathecal Morphine in Dogs”;Anesthesiology; vol. 99 (2003) pp. 174-187.
Ellis David J.
Miljanich George P.
Shields David E.
Azur Pharma International Limited
Kam Chih-Min
Kung Viola T.
Perkins Coie LLP
LandOfFree
Method for reducing pain with ziconotide and baclofen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing pain with ziconotide and baclofen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing pain with ziconotide and baclofen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2687823